DDInter222 DDInter576
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
Bortezomib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Disulfiram
Bortezomib {u} (Compound) upregulates {v} (Gene) FHL2
FHL2 {u} (Gene) is upregulated by {v} (Compound) Disulfiram
Bortezomib {u} (Compound) downregulates {v} (Gene) ADGRE5
ADGRE5 {u} (Gene) is upregulated by {v} (Compound) Disulfiram
Bortezomib {u} (Compound) downregulates {v} (Gene) NR2F6
NR2F6 {u} (Gene) is downregulated by {v} (Compound) Disulfiram
Bortezomib {u} (Compound) upregulates {v} (Gene) SMNDC1
SMNDC1 {u} (Gene) is downregulated by {v} (Compound) Disulfiram
Bortezomib {u} (Compound) causes {v} (Side Effect) Neuropathy
Neuropathy {u} (Side Effect) is caused by {v} (Compound) Disulfiram
Bortezomib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) interacts with {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Disulfiram
Bortezomib {u} (Compound) upregulates {v} (Gene) FHL2
FHL2 {u} (Gene) regulates {v} (Gene) LAMA3
LAMA3 {u} (Gene) is upregulated by {v} (Compound) Disulfiram
Bortezomib {u} (Compound) upregulates {v} (Gene) ABHD4
ABHD4 {u} (Gene) is regulated by {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is upregulated by {v} (Compound) Disulfiram
Bortezomib {u} (Compound) upregulates {v} (Gene) PPP1R15A
PPP1R15A {u} (Gene) interacts with {v} (Gene) MYC
MYC {u} (Gene) is upregulated by {v} (Compound) Disulfiram
Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Disulfiram (Compound)
Bortezomib (Compound) upregulates FHL2 (Gene) and FHL2 (Gene) is upregulated by Disulfiram (Compound)
Bortezomib (Compound) downregulates ADGRE5 (Gene) and ADGRE5 (Gene) is upregulated by Disulfiram (Compound)
Bortezomib (Compound) downregulates NR2F6 (Gene) and NR2F6 (Gene) is downregulated by Disulfiram (Compound)
Bortezomib (Compound) upregulates SMNDC1 (Gene) and SMNDC1 (Gene) is downregulated by Disulfiram (Compound)
Bortezomib (Compound) causes Neuropathy (Side Effect) and Neuropathy (Side Effect) is caused by Disulfiram (Compound)
Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) interacts with STUB1 (Gene) and STUB1 (Gene) is downregulated by Disulfiram (Compound)
Bortezomib (Compound) upregulates FHL2 (Gene) and FHL2 (Gene) regulates LAMA3 (Gene) and LAMA3 (Gene) is upregulated by Disulfiram (Compound)
Bortezomib (Compound) upregulates ABHD4 (Gene) and ABHD4 (Gene) is regulated by HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Disulfiram (Compound)
Bortezomib (Compound) upregulates PPP1R15A (Gene) and PPP1R15A (Gene) interacts with MYC (Gene) and MYC (Gene) is upregulated by Disulfiram (Compound)